Hearing loss in childhood cancer survivors who receive potentially ototoxic therapy (particularly platinum chemotherapy and radiotherapy involving the cochlea) is a well-known, long-term, life-altering complication.1 Known consequences of hearing loss in childhood cancer survivors include academic difficulties,2 social isolation,3 and problems with language acquisition (in children who are prelingual at the time of cancer therapy),4 all of which can significantly impair quality of life.5 While previous studies have suggested an association between severe hearing impairment and neurocognitive deficits in survivors of pediatric central nervous system (CNS) tumors,6-8 to my knowledge, this association has not been clinically evaluated in previous studies of survivors of non-CNS pediatric tumors. In addition, the mediating effect of hearing impairment on neurocognitive outcomes among childhood cancer survivors treated with cranial radiotherapy (CRT) has not been previously examined, to my knowledge.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Landier W. Seeing (Hearing Loss) With Fresh Eyes. JAMA Oncol. Published online July 30, 2020. doi:10.1001/jamaoncol.2020.2639
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: